# Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

> **NCT00927186** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 69 (actual)

## Conditions studied

- Osteoporosis, Post-menopausal

## Interventions

- **DRUG:** Teriparatide
- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00927186
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-10
- **Final completion:** 2012-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927186, "Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00927186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*